Alfasigma S.p.A.: Liver Cirrhosis, Biliary trials
The registry lists 11 Liver Cirrhosis, Biliary studies with Alfasigma S.p.A. as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 2 5Phase 3 2Phase 4 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and BezafibrateTerminatedNCT06488911Phase 3Results posted
- Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsCompletedNCT05292872Results posted
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBCCompletedNCT05239468Phase 2Results posted
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBCTerminatedNCT04594694Phase 2Results posted
- Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic ImpairmentTerminatedNCT03633227Phase 4Results posted
- Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary CholangitisTerminatedNCT02308111Phase 4Results posted
- Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary CirrhosisCompletedNCT01865812Phase 2Results posted
- Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary CirrhosisCompletedNCT01473524Phase 3Results posted
- Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)CompletedNCT00570765Phase 2Results posted
- Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)TerminatedNCT00550862Phase 2Results posted
- A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsWithdrawnNCT05293938